Upstream Manufacturing

INSIGHTS ON UPSTREAM MANUFACTURING

Designing Scalable Cell Therapy For Successful Development
Only 49 cell and gene therapies have reached approval despite 5,000+ active clinical trials. Closing that gap requires designing for commercial-scale manufacturing from the earliest research decisions.
Enhancing AAV Manufacturing Yield Via Mini-Helper Plasmid
Learn how rational plasmid engineering and promoter optimization can significantly improve AAV productivity while reducing plasmid burden, paving the way for more efficient and scalable viral vector manufacturing.
Navigating AI Compliance In Life Sciences: FDA Policy Insights For AI Governance
Navigating life sciences AI compliance requires strong governance, expert human oversight, and transparent, low-risk deployment strategies.
Next-Generation Mesenchymal Stem Cells For Cancer And Regenerative Medicine
Researchers are advancing engineered mesenchymal stem cells using efficient non-viral gene delivery, enabling scalable, targeted therapies for solid tumors while preserving tumor-homing function and manufacturability.

Perfusion Cultivations With ExpiCHO-S Cells Using The Minifors 2 Bioreactor
7/21/2026

High-density perfusion cultivation can support stronger productivity in a smaller footprint. See how integrated cell retention and process control enabled rapid growth, high viable cell densities, and strong IgG titres in eight days.
Human Derived Cell Substrate Characterization
7/20/2026

Safe human cell line use needs key safety, identity, and purity testing steps at each cell bank stage. Robust assay plans assure full regulatory compliance, high safety, and product quality.
Monoclonal Antibody Lot Release Testing For CHO Cell–Derived Products
7/20/2026

Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.
CHO Cell Line Characterization
7/20/2026

Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

Powering Possibilities In Early Phase Development

Streamline early biologics development by combining model-guided sequence selection with parallel scale-up strategies to overcome cell line unpredictability and reduce tech transfer risks.
Enabling Flexibility For T Cell Isolation And Activation Using Workflows

Modular manufacturing strategies can support scalable T-cell processing while maintaining key quality measures. Explore how workflow design choices can help balance efficiency and performance.
Consistone Yeast Extract UF: Batch Versus Fed-Batch Processing

Gain insight into how targeted nutrient supplementation increased CHO cell growth, boosted antibody production, and improved glycosylation profiles across batch and fed-batch cultures.
From Cell Line To Clinic: 4 Months Sooner With mAb Accelerator

Launch cell line development during funding to save four months, beating early bottlenecks and reducing capital risk with milestone-aligned models.
Efficient CLD For Complex Biologics And High-Titer mAbs

We aren't just a CDMO for standard antibodies, we also specialize in taking on the complex molecules (bispecifics, trispecifics, FC-fusions, and more).